- Home
- CODX vs LPCN Comparison
CODX vs LPCN Comparison
Compare CODX & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CODX
- LPCN
- Stock Information
- Founded
- CODX 2013
- LPCN 1997
- Country
- CODX United States
- LPCN United States
- Employees
- CODX N/A
- LPCN N/A
- Industry
- CODX Medical/Dental Instruments
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- CODX Health Care
- LPCN Health Care
- Exchange
- CODX Nasdaq
- LPCN Nasdaq
- Market Cap
- CODX 15.6M
- LPCN 18.2M
- IPO Year
- CODX 2017
- LPCN N/A
- Fundamental
- Price
- CODX $0.40
- LPCN $2.65
- Analyst Decision
- CODX Buy
- LPCN Strong Buy
- Analyst Count
- CODX 2
- LPCN 1
- Target Price
- CODX $2.00
- LPCN $8.00
- AVG Volume (30 Days)
- CODX 60.4M
- LPCN 53.5K
- Earning Date
- CODX 11-13-2025
- LPCN 11-07-2025
- Dividend Yield
- CODX N/A
- LPCN N/A
- EPS Growth
- CODX N/A
- LPCN N/A
- EPS
- CODX N/A
- LPCN N/A
- Revenue
- CODX $1,003,653.00
- LPCN $4,208,119.00
- Revenue This Year
- CODX N/A
- LPCN N/A
- Revenue Next Year
- CODX $31.58
- LPCN N/A
- P/E Ratio
- CODX N/A
- LPCN N/A
- Revenue Growth
- CODX N/A
- LPCN N/A
- 52 Week Low
- CODX $0.23
- LPCN $2.57
- 52 Week High
- CODX $1.55
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- CODX 48.90
- LPCN 36.41
- Support Level
- CODX $0.43
- LPCN $2.75
- Resistance Level
- CODX $0.51
- LPCN $2.92
- Average True Range (ATR)
- CODX 0.14
- LPCN 0.14
- MACD
- CODX -0.00
- LPCN -0.04
- Stochastic Oscillator
- CODX 8.06
- LPCN 12.90
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.